Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study
Huishou Fan, XiangYan Feng, Rongxia Wei, Xin Zhang, Tianlan Li, Lu Liu, Hui Wang, Lingjie Sun, Xue Shi, Hongguo Zhao, Zhao Li, Jingying Cui, Junqing Xu, Junjie Ma, Xianqi Feng, Wei Wang · 2026
Read Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study by Huishou Fan, XiangYan Feng, Rongxia Wei, Xin Zhang, Tianlan Li, Lu Liu, Hui Wang, Lingjie Sun, Xue Shi, Hongguo Zhao, Zhao Li, Jingying Cui, Junqing Xu, Junjie Ma, Xianqi Feng, Wei Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13519186.txt.
Description
Huishou Fan and a large team of co-authors review a three-drug regimen for a blood cancer that has come back, in a 2026 study. The cancer is multiple myeloma, and the regimen pairs carfilzomib and pomalidomide with a steroid. The team gathered records from four hospitals in China to see how the mix performs in everyday care.
Eighty-two patients were included, grouped by how many prior treatments they had received. About seven in ten patients responded, but results were much better in those treated early than in those who had already been through three or more regimens. Serious side effects also grew more common in the later groups. High levels of one blood enzyme and heavy prior treatment marked patients who fared worse. The authors judge the regimen effective and manageable, above all when used early.
Catalog record
| CREATOR | Huishou Fan, XiangYan Feng, Rongxia Wei, Xin Zhang, Tianlan Li, Lu Liu, Hui Wang, Lingjie Sun, Xue Shi, Hongguo Zhao, Zhao Li, Jingying Cui, Junqing Xu, Junjie Ma, Xianqi Feng, Wei Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |